10-Q: Quantum-Si Faces Revenue Drop, Delays Proteus Launch

Quantum-Si Incorporated reported a significant decline in revenue for the second quarter of 2026, attributed to customer anticipation of its next-generation Proteus platform, which has seen its launch date pushed to Q2 2027, alongside a workforce reduction.

Summary

• Quantum-Si Incorporated reported a 41.8% decrease in total revenue for the three months ended June 30, 2026, compared to the same period in 2025, totaling $344,000.
• For the six months ended June 30, 2026, total revenue decreased by 58.0% to $602,000 compared to the prior year.
• The company's next-generation Proteus platform launch has been delayed from the end of 2026 to the second quarter of 2027.
• Quantum-Si announced a restructuring program involving the termination of approximately 20% of its workforce (152 employees), expected to incur charges of $2.6 million in the second half of 2026.
• The company received a Nasdaq deficiency notice on July 23, 2026, for failing to maintain a minimum closing bid price of $1.00 per share, with a compliance deadline of January 19, 2027.
• As of June 30, 2026, the company had $23.7 million in cash and cash equivalents and $88.1 million in current marketable securities, totaling $111.8 million in liquid assets.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to significant revenue declines, a delayed product launch, and a substantial workforce reduction, despite some positive cash management.

Positives

• The company's cash, cash equivalents, and marketable securities totaled $169.9 million as of June 30, 2026, which management believes is sufficient to fund operations for at least the next twelve months.
• Net cash used in operating activities decreased to $44.1 million for the six months ended June 30, 2026, from $46.4 million in the prior year period.
• Net cash provided by investing activities was $48.4 million for the six months ended June 30, 2026, primarily due to proceeds from sales and maturities of marketable securities.
• Selling, general and administrative expenses decreased by 16.1% for the three months ended June 30, 2026, and 17.5% for the six months ended June 30, 2026, compared to the prior year periods.

Negatives

• Total revenue decreased by 41.8% to $344,000 for the three months ended June 30, 2026, and by 58.0% to $602,000 for the six months ended June 30, 2026, compared to the prior year periods.
• Gross profit margin decreased to 50.0% for the three months ended June 30, 2026, and 40.9% for the six months ended June 30, 2026, down from 59.4% and 58.4% respectively in the prior year.
• The launch of the Proteus TM platform has been delayed to the second quarter of 2027, from an original anticipation of the end of 2026.
• The company is terminating approximately 20% of its workforce, impacting about 152 employees, as part of a restructuring program.
• Quantum-Si received a Nasdaq deficiency notice on July 23, 2026, for failing to meet the minimum closing bid price requirement of $1.00 per share.
• Net loss for the three months ended June 30, 2026, was $23.5 million, compared to $28.8 million in the prior year period.
• Net loss for the six months ended June 30, 2026, was $45.2 million, compared to $48.0 million in the prior year period.

Risks

• The delay in the Proteus TM platform launch to Q2 2027, or if it is delivered without desired applications, could materially impact long-term financial success and market credibility.
• Failure to regain compliance with Nasdaq's minimum bid price requirement by January 19, 2027, could lead to delisting, negatively impacting trading price, liquidity, and the ability to raise capital.
• The company may be unable to raise sufficient additional capital when needed, which would negatively impact its financial condition and ability to pursue its business strategy.
• The ongoing restructuring program may result in additional costs not currently contemplated.
• Customer purchasing decisions for existing instruments and consumables may be slowed or delayed in anticipation of the Proteus platform launch.
• The company's ability to utilize or develop artificial intelligence tools effectively and the effects of AI on the business and industry are potential risks.
• International conflicts, pandemics, epidemics, and general economic conditions, including inflation and interest rates, could adversely impact the business.

Future Outlook

The company expects revenue in 2026 to continue to be impacted as customers may delay purchases ahead of the Proteus platform becoming commercially available in Q2 2027. Management believes current cash, cash equivalents, and marketable securities are sufficient to fund operations for at least the next twelve months. Future capital requirements may increase due to product commercialization pace, R&D, potential acquisitions, and operating as a public company.

Management Comments

• Management believes the Company's cash, cash equivalents and marketable securities, together with revenue from the sales of its products and services, will be sufficient to fund its planned operations for at least the next twelve months.
• Until such time as the Company can generate significant revenue from product sales, if ever, it expects to finance its operations through private and public equity offerings, debt financings, and/or potential future collaboration, license and development agreements.
• We expect some customers may delay purchasing decisions for existing products, which is expected to adversely impact revenue until Proteus becomes commercially available.
• We expect gross profit margin to be variable for the foreseeable future as we work through our continued commercialization efforts.

Industry Context

StockSavvy.ai notes that Quantum-Si operates in the highly competitive and rapidly evolving proteomics tools market. The delay in its next-generation platform, Proteus, and the subsequent workforce reduction suggest potential challenges in execution and market positioning against competitors with potentially greater financial and marketing resources.

Comparison to Industry Standards

• The revenue decline of 58.0% for the six-month period is significantly worse than typical performance for established life science tool companies, which often aim for mid-to-high single-digit or double-digit growth.
• The delay of a key product launch (Proteus) by over six months (from end of 2026 to Q2 2027) is a notable setback, as industry leaders typically strive for more predictable product development timelines.
• The workforce reduction of 20% indicates a significant strategic shift or cost-cutting measure, which is not uncommon during challenging periods but highlights potential financial strain.
• The Nasdaq bid price deficiency below $1.00 is a critical concern, as many companies in the sector aim to maintain a strong stock price to facilitate capital raising and investor confidence.

Management Changes

Legal Proceedings

• The Delaware Stockholder Litigation, filed on May 16, 2024, asserted breach of fiduciary duty claims related to the Business Combination. A preliminary settlement was reached in July 2025 and approved by the court on March 27, 2026. The company recorded an $8.0 million liability and a $4.6 million receivable, with the receivable funded by insurance. The liability and receivable were derecognized in Q1 2026.

Related Party Transactions

• The company previously participated in an Amended and Restated Technology Services Agreement (ARTSA) with 4Catalyzer Corporation and other participant companies controlled by Dr. Jonathan Rothberg. The company's participation terminated prior to the Business Combination on June 10, 2021. No expenses were paid to 4C for the three and six months ended June 30, 2026. Immaterial expenses were paid in the prior year period for month-to-month sublease arrangements and administrative services.

Stakeholder Impact

• Shareholders: Potential negative impact due to revenue decline, product launch delay, workforce reduction, and Nasdaq delisting risk. Positive impact from management's belief in sufficient liquidity for the next 12 months.
• Employees: Significant negative impact due to the termination of approximately 20% of the workforce.
• Customers: Potential for delayed purchasing decisions due to anticipation of the Proteus platform, but also potential long-term benefit from improved technology.
• Creditors: No immediate negative impact indicated, as the company has sufficient liquidity.

Next Steps

• Regain compliance with Nasdaq's minimum bid price requirement by January 19, 2027.
• Complete the 2026 Restructuring Program by the end of 2026.
• Continue development and prepare for the commercial launch of the Proteus TM platform in Q2 2027.
• Manage liquidity and operations with existing cash and marketable securities, and potentially through future financing activities.

Key Dates

Recommendation

The company faces significant headwinds with declining revenues, a delayed product launch, and a Nasdaq delisting risk. However, it maintains substantial liquidity and is undertaking restructuring. A 'hold' recommendation reflects the uncertainty and risk, balanced by the potential for future recovery if the Proteus platform is successful and compliance with Nasdaq is achieved.

Keywords

proteomics, single-molecule sequencing, Proteus platform, Platinum Pro, life sciences, biomarker discovery, instrumentation, consumables